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Streptozotocin (2deoxy-2-(3.methyl3nitro- 
sourea)ldglucopyranose) (ol t /3) is an antibiotic iso- 
lated in 1959 from Streptomyces achromogenes var. 
~tre~tuzotic~s found in a soil sample collected at 
Blue Rapids, Kansas. The wide range of biological 
effects of this material were discussed as follows: 
history, diabetogenesis and the underlying mecha- 
nisms, tumorigenesis, clinical applications. 
The complete structural detestation was 
reported in 1979 althou~ chemical synthesis was 
accomplished as early as 1967. WeIl over a hundred 
analogues are actually known. In the natural state, 
streptozotocin exists as a 50-50 mixture of (Y and 
0 anomers. In about one third of the analogues, the 
basic streptozotoc~ structure has been retained but 
modifications include acetylations, alkylations, 
replacement of the nitroso group. The acetyl deriva- 
tives are as active as the parent molecule. The alkyl 
glycoside analogues exhibit substantially reduced 
antibacterial property but retain antitumour activity. 
Replacement of the methyl group by 2-chloroethyl 
results in chlorzotocin that seems uperior to strep- 
tozotocin as a clinically useful anti-tumour agent. The 
usefulness of other chemical modifications is less cer- 
tam (Wiley). 
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Experimental diabetes can be produced transiently 
by hormones (glucagon, somatotropin, glucocorti- 
coids, adrenaline, sex steroids), cyproheptadine, 
L-asparaginase, qu~o~es and related compound, 
benzothiodiazine diuretics, hypotensives. Permanent 
diabetes by alloxan or streptozotocin revealed that 
both produced irreversible damage to pancreatic 
&cells; streptozotocin can also destroy the o-cells and 
the D-cells in the Chinese hamster. Both chemicals 
produce an initial rise in blood sugar in the first 4 h 
post injection followed by hypoglycemia between 
6-l 2 h, and finally permanent hyperglycemia 24 h 
post treatment. These are due, respectively, to an 
initial inhibition of insulin release, feedback increase 
in plasma insulin, and insulin deficiency due to P-cell 
destruction. 
The two compounds differ in many respects. The 
half life of streptozotocin is 10-l 5 min and that of 
alloxan 1 min, after intravenous administration. Liver 
and islet NAD levels decrease after streptozotocin 
but not after alloxan. or-Glucose inhibits the action 
of alloxan but not that of streptozotocin. Nicotin- 
amide, but not nicotonic acid, protects against strep- 
tozotocin but both antagonise alloxan mediated 
diabetogenesis. Nicotinamide will protect if given 
even 2 h after streptozotocin but it must be given 
s~ultaneou~y or before alloxan. ~raz~~ide, 
diphenylhydanto~, and 2-deoxyglucose will also 
antagonise streptozotocin action. 
As to the mechanisms of diabetogenesis, the glu- 
cose moiety of the a-anomer is believed to act as a 
carrier for the ~~itroso-~-methyl-urea portion. Intra- 
cellular entry of streptozotoc~ leads to hype~rophy 
of P-cell Golgi apparatus within 1 h, and cell pycnosis 
follows shortly. Alloxan is believed to react with the 
extracellular receptor for glucose on the P-cell surface 
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leading to increased permeability and, within 5 min, 
cytoplasmic fragmentation and chromatin clumping. 
Morphological changes of cytolysis are similar 4-5 h 
after either chemical. 
streptozotocin (Baba). However, in other conditions 
(DeHertogh) long survival did not lead to tumour 
formation. 
Reversion to the normal state is more frequent 
with alloxan than with streptozotocin. Indeed, dia- 
betes induced by streptozotocin is more akin to 
juvenile onset diabetes in the human, than alloxan 
induced diabetes. Both the early and the late changes 
in renal complications, following natural human dia- 
betes and after streptozotocin in the rat, are very 
comparable (Rasch). 
There are great species specific differences in 
diabetogenesis and the underlying changes in the 
enzymes of the carbohydrate pathway in response to 
streptozotocin administration (Chang). The sensi- 
tivity to streptozotocin diabetes may be established 
as rat > mouse > dog > guinea pig. Other aspects of 
streptozotocin action include hypertriglyceridemia 
(Reaven), muscle protease activity (Dahlman), altered 
lipid metabolism (Stearns), microvascular disease 
(Reddi), collagen metabolism (Schnier), immuno- 
suppression (Nichols). 
Cyclases are currently believed to be related to 
growth. Dr Vesley (Little Rock) attempted to corre- 
late guanylate cyclase activity with tumour induction 
by streptozotocin. The activity of this enzyme was 
increased by streptozotocin in vitro in the order: 
liver > cerebrum > heart > kidney cerebellum > 
brain stem > lung > spleen > pancreas. It was 
pointed out that the smallest increases in the pancreas 
did not parallel streptozotocin induced pancreatic 
tumours, and moreover the studies did not show 
any streptozotocin effect on this enzyme in vivo 
(Agarwal). Dr Kazumi (Kobe) suggested that the 
enzyme assays on isolated islets may be more mean- 
ingful than on the whole pancreas but Dr Vesley indi- 
cated that this was difficult to do and that the activ- 
ity of this enzyme may have more of a predictive 
value for streptozotocin therapy than for oncogenic 
action of the antibiotic. 
The general consensus was to acceptthe view that 
streptozotocin is a particularly appropriate experimen- 
tal tool for studying the pathology of natural diabetes 
in the human (Rasch) and in this respect several injec- 
tions of smaller doses of streptozotocin appeared to be 
more effective than a single large bolus (Agarwal). 
In an effort to understand the complications of 
pregnancy in diabetic women, Dr DeHertogh 
(Louvain) showed that the early oestrogen action 
and receptor kinetics in rat uterus are not altered 
after long term streptozotocin treatment. Similarly, 
the association of glucocorticoid hormones with their 
hepatic receptor seems unimpaired in streptozotocin 
diabetic mice (Agarwal). 
Pancreatic endocrine tumours and carcinoids, 
collectively called apudomas, have classically bene- 
fitted from surgical resection but many patients 
exhibit metastases at the time of diagnosis and this 
led to the search for a specific chemotherapeutic 
agent. As early as 1969 the affinity of streptozotocin 
for P-cells was exploited for tumour destruction and 
more than one hundred patients have been treated 
thus far. Most tumours are composed of several cell 
types and secrete many biologically active peptides. 
These include gastrin, vasoactive-intestinal poly- 
peptide, calcitonin, pancreatic polypeptide, soma- 
tostatin all of which originate from the entero- 
chromaffinlike cells in the pancreas and the mid gut. 
Insulinomas and glucagonomas are strictly pancreatic 
in origin. 
The l-methyl-1-nitrosourea moiety of strepto- As compared to L-asparaginase, S-fluorouracil, 
zotocin may be responsible for oncogenesis in the tubericidin, adriamycin, mithramycin, glucose, and 
kidney, liver, peritoneum, and pancreas of the rat. glucocorticoid hormones, streptozotocin is by far the 
Abnormal regeneration of all cell types in the pan- most potent agent if given as 1-2 g/m’ intrave- 
creas, possibly aided by hyperglycemia, may lead to nously per week to a total of 6-8 g with subsequent 
P-cell adenoma (Fox). The tumours have very low maintenance in low doses, dissolved in titrated saline 
glucagon levels and large amounts of insulin and are pH 4.5. In an earlier study, out of 30 cases, 50% 
thus multicellular and multihormonal (Baba). Curi- benefitted from a diminished tumoral mass, 17% 
ously, nicotinamide actually helps streptozotocin exhibited complete remission, 64% showed favour- 
mediated oncogenesis and this was confirmed by the able biochemical responses and in 26% insulin levels 
group of Professor Baba (Kobe). Thus, diabetogenesis returned to normal. These were confirmed on 19 cases 
and tumorigenesis are two distinct functions where of pancreatic tumours by Dr Oberg (Stockholm). The 
the latter is essentially a result of long survival after drug was of limited value in treating carcinoid 
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turnours in 12 patients (Oberg). It is less certain 
whether streptozotocin can be used to treat Hodgkin’s 
disease, lymphocytic lymphoma, and other carci- 
nomas (lung, oral cavity) although such efforts have 
been made. 
The major problem with the drug is its high toxi- 
city for the kidney which can be avoided by monitor- 
ing uterine protein; the next dose should not be admi- 
nistered until the proteinuria drops to zero. Other 
side effects include nausea, vomit&g, toxicity on the 
liver and the he~to~ietic system. The affinity of 
the drug for the &cell is shown by the fact that 
insulinomas are effectively destroyed but glucago- 
nomas are far more resistant. Thus, diabetes may 
eventually become a complication of streptozotocin 
therapy. Other side effects have not yet been worked 
out but are evident from the influence of strepto- 
zotocin on various types of tumours, especially VIP- 
omas that are very sensitive to the antineoplastic 
effect. 
Agarwal et al. (Paris) presented evidence that 
streptozotocin may not be as specific a P-cell toxin 
as hitherto believed. P-cell destruction and hyper- 
glycemia take 24 h to manifest hemselves but the 
drug can sensitize mice to endotoxin lethality in the 
first few hours after intraperitoneal dministration._ 
Dr Vesley suggested that early effects are difficult to 
tie in with affinity for the P-cell and its eventual 
destruction. The multiple hit hypothesis is also sup- 
ported by the activity in the Chinese hamster where 
all pancreatic ells are attacked, and by effects of 
streptozotocin on various types of tumours indicated 
above (Agarwal). 
In conclusion, streptozotocin isunusually effective 
in simulating human juvenile onset diabetes in exper- 
imental animals. It may also be a good model for 
understanding host regulation at the level of immu- 
nology, physiology, pharmacology and biochemis- 
try. Although it may have more than one site of 
action in the beginning, the long term effects can be 
explained by its affinity for the p-cell of the pancreas. 
In the long run, streptozotocin may be of great 
importance not only in understanding the mecha- 
nisms of diabetogenesis and oncogenesis but also as 
an antitumour agent for which the Food and Drug 
Administration has just approved the patent for pro- 
duction by the Upjohn Co. for therapy of apudomas. 
Full proceedings of the meeting are to be published 
by Elsevier/North-Ho~and, Amsterdam, New York. 
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